Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.
